ID

23355

Beskrivning

Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00359879

Länk

https://clinicaltrials.gov/show/NCT00359879

Nyckelord

Versioner (1)
  1. 2017-07-03 2017-07-03 -
Uppladdad den

3 juli 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Type 2 Diabetes NCT00359879

Engelsk

Eligibility Type 2 Diabetes NCT00359879

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with type 2 diabetes.
Beskrivning

Diabetes Mellitus, Non-Insulin-Dependent

Datatyp

boolean

Alias
UMLS CUI [1]
C0011860
have been treated with one of the following treatment regimens for at least three months prior to screening: *metformin alone; *sulfonylurea (su) alone;
Beskrivning

Metformin | Sulfonylurea

Datatyp

boolean

Alias
UMLS CUI [1]
C0025598
UMLS CUI [2]
C0038766
*thiazolidinedione (tzd) alone; *a combination of metformin and su; *a combination of metformin and tzd.
Beskrivning

Thiazolidinediones | Metformin | Sulfonylurea

Datatyp

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0038766
hba1c between 7.1% and 10.0%, inclusive.
Beskrivning

Glycosylated hemoglobin A

Datatyp

boolean

Alias
UMLS CUI [1]
C0019018
body mass index (bmi) > 25 kg/m^2 and < 45 kg/m^2
Beskrivning

Body mass index

Datatyp

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental drug, medical, or surgical treatment was given) within 30 days prior to screening.
Beskrivning

Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0184661
UMLS CUI [3]
C0087111
UMLS CUI [4]
C0543467
UMLS CUI [5]
C0013230
have characteristics contraindicating metformin, su, or tzd use.
Beskrivning

Medical contraindication Metformin | Medical contraindication Sulfonylurea | Medical contraindication Thiazolidinediones

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0025598
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0038766
UMLS CUI [3,1]
C1301624
UMLS CUI [3,2]
C1257987
are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
Beskrivning

Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0744425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C0205191
UMLS CUI [2]
C0017712
UMLS CUI [3,1]
C0017710
UMLS CUI [3,2]
C0205535
have used any prescription drug to promote weight loss within 3 months prior to screening.
Beskrivning

Weight-Loss Agents

Datatyp

boolean

Alias
UMLS CUI [1]
C0376606
are currently treated (for greater than 2 consecutive weeks) with any of the following excluded medications: *insulin within 3 months prior to screening;
Beskrivning

Insulin

Datatyp

boolean

Alias
UMLS CUI [1]
C0021641
*alpha-glucosidase inhibitors within 3 months prior to screening; *meglitinides within 3 months prior to screening; *drugs that directly affect gastrointestinal motility
Beskrivning

alpha-Glucosidase Inhibitors | Meglitinide | Pharmaceutical Preparations Affecting Gastrointestinal Motility

Datatyp

boolean

Alias
UMLS CUI [1]
C1299007
UMLS CUI [2]
C0065880
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C0017184
Tillbaka till toppen

Similar models

Eligibility Type 2 Diabetes NCT00359879

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
Metformin | Sulfonylurea
Item
have been treated with one of the following treatment regimens for at least three months prior to screening: *metformin alone; *sulfonylurea (su) alone;
boolean
C0025598 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
Thiazolidinediones | Metformin | Sulfonylurea
Item
*thiazolidinedione (tzd) alone; *a combination of metformin and su; *a combination of metformin and tzd.
boolean
C1257987 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
Glycosylated hemoglobin A
Item
hba1c between 7.1% and 10.0%, inclusive.
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) > 25 kg/m^2 and < 45 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs
Item
have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental drug, medical, or surgical treatment was given) within 30 days prior to screening.
boolean
C2348568 (UMLS CUI [1])
C0184661 (UMLS CUI [2])
C0087111 (UMLS CUI [3])
C0543467 (UMLS CUI [4])
C0013230 (UMLS CUI [5])
Medical contraindication Metformin | Medical contraindication Sulfonylurea | Medical contraindication Thiazolidinediones
Item
have characteristics contraindicating metformin, su, or tzd use.
boolean
C1301624 (UMLS CUI [1,1])
C0025598 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0038766 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C1257987 (UMLS CUI [3,2])
Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation
Item
are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
boolean
C0744425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0017712 (UMLS CUI [2])
C0017710 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
Weight-Loss Agents
Item
have used any prescription drug to promote weight loss within 3 months prior to screening.
boolean
C0376606 (UMLS CUI [1])
Insulin
Item
are currently treated (for greater than 2 consecutive weeks) with any of the following excluded medications: *insulin within 3 months prior to screening;
boolean
C0021641 (UMLS CUI [1])
alpha-Glucosidase Inhibitors | Meglitinide | Pharmaceutical Preparations Affecting Gastrointestinal Motility
Item
*alpha-glucosidase inhibitors within 3 months prior to screening; *meglitinides within 3 months prior to screening; *drugs that directly affect gastrointestinal motility
boolean
C1299007 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0017184 (UMLS CUI [3,3])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial